← Back to Search

Monoclonal Antibodies

Treatment (daratumumab) for Myelodysplastic Syndrome

Phase 2
Waitlist Available
Led By Gautam Borthakur
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3.5 years
Awards & highlights

Summary

This trial studies how well daratumumab and venetoclax work in treating patients with certain types of leukemia and myelodysplastic syndrome that are hard to treat or have returned. The treatment boosts the immune system to attack cancer cells and prevents them from surviving. Daratumumab has been used in the treatment of multiple myeloma and has shown efficacy in relapsed or refractory cases.

Eligible Conditions
  • Myelodysplastic Syndrome
  • Acute Myeloid Leukemia
  • Acute Myelogenous Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3.5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3.5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Participants With a Response
Secondary study objectives
Overall Survival
Progression Free Survival
Time on Treatment
Other study objectives
Biomarkers predictive of response or resistance to therapy

Side effects data

From 2024 Phase 3 trial • 498 Patients • NCT02136134
44%
Thrombocytopenia
38%
Peripheral sensory neuropathy
38%
Peripheral Sensory Neuropathy
32%
Anaemia
24%
Fatigue
22%
Diarrhoea
17%
Upper respiratory tract infection
17%
Upper Respiratory Tract Infection
16%
Constipation
15%
Insomnia
15%
Asthenia
13%
Cough
11%
Nausea
11%
Neuralgia
11%
Pyrexia
11%
Dizziness
10%
Neutropenia
10%
Back pain
10%
Back Pain
10%
Pneumonia
9%
Dyspnoea
8%
Oedema peripheral
8%
Oedema Peripheral
7%
Hyperglycaemia
7%
Pain in extremity
6%
Pain in Extremity
6%
Bronchitis
6%
Headache
6%
Paraesthesia
6%
Arthralgia
5%
Dyspepsia
5%
Bone pain
5%
Decreased appetite
5%
Bone Pain
5%
Hypocalcaemia
5%
Decreased Appetite
5%
Epistaxis
5%
Leukopenia
5%
Hypokalaemia
4%
Lymphopenia
4%
Vomiting
4%
Oedema
4%
Hypotension
4%
Abdominal pain
4%
Alanine aminotransferase increased
4%
Nasopharyngitis
4%
Alanine Aminotransferase Increased
3%
Rash
3%
Hypertension
3%
Abdominal Pain Upper
3%
Conjunctivitis
3%
Abdominal pain upper
3%
Influenza
3%
Hypophosphataemia
2%
Myalgia
2%
Aspartate aminotransferase increased
2%
Muscle Spasms
2%
Muscle spasms
2%
Musculoskeletal Chest Pain
2%
Urinary tract infection
2%
Herpes zoster
2%
Musculoskeletal chest pain
2%
Herpes Zoster
1%
Syncope
1%
Pulmonary Embolism
1%
Weight Decreased
1%
Pulmonary embolism
1%
Respiratory failure
1%
Nasal congestion
1%
Productive cough
1%
Lower respiratory tract infection
1%
Myocardial Infarction
1%
Myocardial infarction
1%
General physical health deterioration
1%
Lower Respiratory Tract Infection
1%
Abdominal Pain
1%
Orthostatic Hypotension
1%
General Physical Health Deterioration
1%
Dehydration
1%
Hyponatraemia
1%
Condition aggravated
1%
Orthostatic hypotension
1%
Weight decreased
1%
Chills
1%
Gastroenteritis
1%
Sepsis
1%
Respiratory Failure
1%
Condition Aggravated
100%
80%
60%
40%
20%
0%
Study treatment Arm
Bortezomib + Dexamethasone (Vd)
Daratumumab + Bortezomib and Dexamethasone (DVd)
Switch From Bortezomib + Dexamethasone (Vd) to Daratumumab Monotherapy

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (daratumumab)Experimental Treatment1 Intervention
Patients receive daratumumab IV over 3.25-6.5 hours on days 1, 8, 15 and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and on day 1 of subsequent cycles. Cycles repeat every 28 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Daratumumab
2014
Completed Phase 3
~2000

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,041 Previous Clinical Trials
1,799,733 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,855 Previous Clinical Trials
41,006,070 Total Patients Enrolled
Gautam BorthakurPrincipal InvestigatorM.D. Anderson Cancer Center
4 Previous Clinical Trials
426 Total Patients Enrolled
~1 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top